---
title: "From Immune Response to Public Health: Estimating Influenza Vaccine Protection Across Scales"
subtitle: "Proposal Defense Practice, IDIG"
date: "March 13, 2025"
author: "Savannah M. Hammerton"
execute: 
  echo: false
  warning: false
  message: false
format: 
  revealjs:
    scrollable: false
    slide-number: true
    toc: false
    self-contained: true
    lightbox: true
    link-external-newwindow: true
    theme: [default, custom.scss]
bibliography: ../../assets/references/proposal.bib
---

# Background

## Influenza 

![](flu-burden-2425.png){height=500 fig-align="center"}

::: aside
@cdc25
:::

## Influenza

:::: {.columns}

::: {.column width=50%}

![](news1.png)

![](news2.png)

:::

::: {.column width=50%}
![](news3.png)

![](news4.png)

:::

::::

## Influenza

:::: {.columns}

::: {.column width=50%}

![](cdc-influenza.png){height=400}



:::

::: {.column}
-   Enveloped negative-sense single-strand RNA virus
-   Segmented genome (8 segmenets)
-   HA facilitates viral entry 
-   NA facilitates viral release
:::
::::

::: aside

@cdc24b; @krammer18

:::

## Influenza Classification 

:::: {.columns}

::: {.column width="50%"}

- Types and Subtypes:

  - **A/H1N1**
  - **A/H3N2**
  - A/H5N1
  - **B/Victoria**
  - ~~B/Yamagata~~
  - C
  - D
  


:::

::: {.column width="50%"}

- Strains [@who24]:

  - A/Victoria/4897/2022 (H1N1)pdm09-like virus
  - A/Thailand/8/2022 (H3N2)-like virus
  - B/Austria/1359417/2021 (B/Victoria lineage)-like virus

:::

::::

## Influenza Vaccines 

::: {style="font-size: 90%;"}

Strains are chosen/recommended each year based on [@cdc24a]:

- Which influenza viruses are making people sick prior to the upcoming flu season,
- The extent to which those viruses are spreading prior to the upcoming flu season,
- How well the previous season's vaccines may protect against those influenza viruses, and
- The ability of vaccine viruses to provide cross-protection against a range of related influenza viruses of the same type or subtype/lineage.

:::

## Influenza Vaccines

![](DAG1.png){height=525 fig-align="center"}

::: aside
Created with BioRender.com
:::

## Influenza Vaccines

![](DAG2.png){height=525 fig-align="center"}

::: aside
Created with BioRender.com
:::

## Influenza Vaccines

![](DAG3.png){height=525 fig-align="center"}

::: aside
Created with BioRender.com
:::

## Influenza Vaccines

![](DAG4.png){height=525 fig-align="center"}

::: aside
Created with BioRender.com
:::

## Influenza Vaccines

![](DAGFinal.png){height=525 fig-align="center"}

::: aside
Created with BioRender.com
:::

## Problem/Significance

![](cdc-ve.png)

::: aside
VE is variable and often low; @cdc24c
:::

## Problem/Significance

:::: {.columns}

::: {.column width=40%}

::: {style="font-size: 70%;"}

- Why is VE so low? Many different theories (probably a combination):
  - Original antigenic sin/imprinting
  - Low immunogenicity 
  - Match/Mismatch between vaccine strain and circulating strain
  
:::

:::

::: {.column}

![](vaccine-match-mismatch.png)

::: aside
Created with BioRender.com
:::

:::

::::


## Specific Aims

1. Identify and model correlates of protection against influenza in animal models.

2. Evaluate benefit of high-dose influenza vaccination by estimating and comparing Fluzone vaccine efficacies in age- and dose-based groups.

3. Quantify the impact of antigenic distance between vaccine and circulating influenza strains on vaccine effectiveness.

# **Aim 1.** Identify and model correlates of protection against influenza in animal models.

## Correlates of Protection

-   Biomarker associated with protection against infection or disease 
-   Related terms: surrogate, mechanistic/nonmechanistic correlate, mediator of protection
-   Nomenclature often depends on the believed causality of the marker

::: aside
@lim20; 
:::

## CoPs in Humans 

:::: {.columns}
::: {.column width=50%}
![](coudeville.png){height=200}
:::

::: {.column}
![](dudasova.png){height=215}
:::

::::

![](cowling18.png){height=250 fig-align="center"}


::: aside
From top left: @coudeville10; @dudasova2021; @cowling2019
:::

::: {.notes}
-   Hobson 1972(date?) 1:40 50%PT
:::

## [Planned] Data Description

![](mouse_timeline.png){height=550 fig-align="center"}

::: aside
Created with BioRender.com
:::

::: {.notes}
-   We are still working on data requests with bench scientists at UGA (and potentially elsewhere) who perform animal studies that follow this basic timeline. 
-   Essentially, we will request data sets that have mice or ferrets who are pre-immune and/or vaccinated at the beginning of the study, with pre-challenge HAI titers, reasonable inoculations (AKA not 10x the lethal dose), and follow up with infection and disease outcomes.
:::

## Proposed Study {.smaller}

:::: {.columns}

:::{.column width=40%}

-   Analyze mouse and ferret (two most common influenza animal models) data separately 
-   Bayesian mixed-effects models 


![](haicopblank.png)


:::

:::{.column}


-   Outcomes to assess:
    - PCR confirmed infection
    - Weight loss/anorexia
    - Time to illness
    - Viral load
-   Account for:
    - Immunity source
    - Inoculum dose
    - Study site 

:::

::::

::: aside
Created with BioRender.com
:::

## Proposed Study {.smaller}

:::: {.columns}

:::{.column width=40%}

-   Analyze mouse and ferret (two most common influenza animal models) data separately 
-   Bayesian mixed-effects models 


![](haicop.png)


:::

:::{.column}


-   Outcomes to assess:
    - PCR confirmed infection
    - Weight loss/anorexia
    - Time to illness
    - Viral load
-   Account for:
    - Immunity source
    - Inoculum dose
    - Study site 

:::

::::

::: aside
Created with BioRender.com
:::

# **Aim 2.** Evaluate benefit of high-dose influenza vaccination by estimating and comparing Fluzone vaccine efficacies in age- and dose-based groups.

## Immunogenicity Studies 

:::: {.columns}

::: {.column width=50%}

![](DAGFinal.png){height=350}

:::

::: {.column}

-   Efficacy studies time and resource intensive 
-   Immunogenicity studies typically more sustainable and done more regularly/for longer periods
-   Still useful to bring results back to actual protection

:::

::::

::: aside
Created with BioRender.com
:::


::: {.notes}
-   
:::

## Data Description

## Study Methods

![](coudeville.png){height=525}

::: aside
@coudeville10
:::

## Study

![](combined_ve.png)


::: aside
@hammerton24
:::

## Study

![](oasd_yasd.png){height=500 fig-align="center"}

::: aside
@hammerton24
:::

## Study

![](oahd_oasd.png){height=500 fig-align="center"}

::: aside
@hammerton24
:::

## Study

![](oahd_yasd.png){height=500 fig-align="center"}

::: aside
@hammerton24
:::

# **Aim 3.** Quantify the impact of antigenic distance between vaccine and circulating influenza strains on vaccine effectiveness.

## Antigenic Match and Mismatch

![](vaccine-match-mismatch.png){height=550}


::: aside
Created with BioRender.com
:::

## Previous Literature

:::: {.columns}

::: {.column width=50%}

![](article4.png)

![](article2.png)
:::

::: {.column width=50%}

![](article3.png)

![](article1.png) 


:::

::::

## [Planned] Data Description



## Proposed Study

```{r}
readRDS(
  here::here("presentations/proposal-idig/tb1_shell.rds")) |> 
  flextable::autofit() 
```

## Analysis Plan

:::: {.columns}

::: {.column width=40%}

- Primary modeling result: what is the association between VE and antigenic distance? 

:::

::: {.column width=60%}

![](VE-AgDist-Options.png)

::: aside
Created with BioRender.com
:::

:::

::::





















# Acknowledgements {.smaller}

Committee

:::: {.columns}

::: {.column width=15%}



![Andreas Handel](ah.jpg){width=2in}

![Zane Billings](zb.jpg)

:::

::: {.column width=15%}
![Ye Shen](ys.jpg){width=2in}

![Ted Ross](tr.jpg)
:::

::: {.column width=15%}
![Amy Winter](aw.jpg){width=2in}

![George Okoli](go.jpg){width=2in}
:::

::: {.column width=15%}
![Ben Cowling](bc.jpg){width=2in}

![Funding](civics.jpg){width=2in}

:::


::: {.column width=15%}

![](cph.png)

![](cider.png){width=2in}

:::

::: {.column width=15%}
- Handelgroup
- IDIG
- 
:::

::::

# References